Delcath Systems/$DCTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Delcath Systems
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Ticker
$DCTH
Sector
Primary listing
Employees
156
Headquarters
Website
Delcath Systems Metrics
BasicAdvanced
$378m
809.19
$0.01
0.53
-
Price and volume
Market cap
$378m
Beta
0.53
52-week high
$17.35
52-week low
$8.12
Average daily volume
416k
Financial strength
Current ratio
11.242
Quick ratio
9.671
Long term debt to equity
0.723
Total debt to equity
0.805
Profitability
EBITDA (TTM)
-1.322
Gross margin (TTM)
85.97%
Net profit margin (TTM)
0.62%
Operating margin (TTM)
-1.79%
Effective tax rate (TTM)
58.07%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
-0.95%
Return on equity (TTM)
0.58%
Valuation
Price to earnings (TTM)
809.193
Price to revenue (TTM)
4.379
Price to book
3.35
Price to tangible book (TTM)
3.35
Price to free cash flow (TTM)
20.633
Free cash flow yield (TTM)
4.85%
Free cash flow per share (TTM)
0.531
Growth
Revenue change (TTM)
67.95%
Earnings per share change (TTM)
-102.95%
3-year revenue growth (CAGR)
213.40%
10-year revenue growth (CAGR)
49.03%
3-year earnings per share growth (CAGR)
-84.67%
What the Analysts think about Delcath Systems
Analyst ratings (Buy, Hold, Sell) for Delcath Systems stock.
Delcath Systems Financial Performance
Revenues and expenses
Delcath Systems Earnings Performance
Company profitability
Delcath Systems News
AllArticlesVideos
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 weeks ago
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs